DRI Healthcare Comments on Viridian's FDA Approval and Launch of Lumvoa(TM) (veligrotug-vvze)

About this update from Dri Healthcare Trust

DRI Healthcare Comments on Viridian's FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } .prntac{ TEXT-ALIGN: CENTER } Canada NewsWire - First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED -- DRI Healthcare is entitled to a tiered royalty on annual U.S. net sales of Viridian's TED franchise -TORONTO, June 29, 2026 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today commented on Viridian Therapeutics, Inc.'s ("Viridian") recently announced approval by the U.S. Food and Drug Administration ("FDA") of Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease ("TED"). TED is an autoimmune inflammatory disorder of the orbit (eye socket) that affects numerous patients in the U.S. and can cause debilitating and disfiguring eye symptoms (e.g., inflammation, proptosis, and double-vision) with severe disease leading to vision loss. DRI Healthcare is entitled to receive a tiered royalty on annual U.S. net sales of Viridian's TED franchise. In connection with the FDA approval of Lumvoa™ (veligrotug-vvze), DRI Healthcare will make a milestone payment of US$75 million to Viridian pursuant to the terms of its existing royalty agreement with Viridian."We are pleased to see Viridian achieve FDA approval and launch Lumvoa™ (veligrotug-vvze) in the United States," said Ali Hedayat, Chief Executive Officer of DRI Healthcare. "This milestone reinforces DRI Healthcare's strategy of allocating capital to differentiated therapies with meaningful clinical value, while seeking to generate attractive returns for our unitholders.""Congratulations to the Viridian team on the approval of Lumvoa™ (veligrotug-vvze) which is poised to provide patients with TED a new treatment option with greater convenience.  We look forward to seeing the continued progression of Viridian's second-generation TED product candidate, elegrobart. This product, if approved, could provide even greater convenience as the first true subcutaneous auto-injector for TED" said Navin Jacob, Chief Inve...

View stock analysis, news, and events for Dri Healthcare Trust